National Cancer Institute

DLH to Provide Information Technology Services to the National Cancer Institute

Retrieved on: 
목요일, 3월 7, 2024

NCI, the largest institute under NIH, is the federal government's principal agency for cancer research, training, and health information dissemination.

Key Points: 
  • NCI, the largest institute under NIH, is the federal government's principal agency for cancer research, training, and health information dissemination.
  • “This new award extends DLH’s longstanding partnership with NCI’s Center for Biomedical Informatics and Information Technology (“CBIIT”) by providing scientific computing and informatics to support NCI’s research mission,” said Zach Parker, President and Chief Executive Officer of DLH.
  • The contract was competitively awarded through the multiple-award blanket purchase agreement with CBIIT that the Company announced in February 2023.
  • Through this work, DLH will provide IT services for nearly 7,000 NCI employees, on matters ranging from hardware configuration to software management strategies, ServiceNow functions, network connectivity, desktop data protection, desktop platform engineering, technology refresh, and more.

Adagene Appoints Heinz-Josef Lenz, M.D., FACP to Scientific and Strategic Advisory Board

Retrieved on: 
목요일, 3월 7, 2024

SAN DIEGO and SUZHOU, China, March 07, 2024 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of antibody-based therapies, today announced the appointment of Heinz-Josef Lenz, M.D., FACP, to its Scientific and Strategic Advisory Board (the “SAB”).

Key Points: 
  • SAN DIEGO and SUZHOU, China, March 07, 2024 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of antibody-based therapies, today announced the appointment of Heinz-Josef Lenz, M.D., FACP, to its Scientific and Strategic Advisory Board (the “SAB”).
  • Dr. Lenz accelerates translational and clinical research and provides training and mentoring in the design and implementation of investigator-initiated trials.
  • In 1991, he completed his internship, residency, and fellowship training at the Eberhardt Karls Universität in Tübingen, Germany.
  • “His insight and clinical experience as a leading expert in colorectal cancer is of great importance as we develop our SAFEbody® ADG126 for patients worldwide.”
    For more information about members of the Adagene Scientific and Strategic Advisory Board, visit: https://www.adagene.com/about/key-advisors/

Gritstone bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates

Retrieved on: 
화요일, 3월 5, 2024

EMERYVILLE, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today reported financial results for the fourth quarter and full year ended December 31, 2023 and provided recent corporate and clinical updates.

Key Points: 
  • Positive signal in this metastatic context would likely unlock enormous opportunity in both adjuvant and metastatic solid tumors.
  • Gritstone met its enrollment target of 100 patients randomized in August 2023.
  • Cash, cash equivalents, marketable securities and restricted cash were $86.9 million as of December 31, 2023, compared to $185.2 million as of December 31, 2022.
  • Research and development expenses were $127.2 million for the year ended December 31, 2023 compared to $111.4 million for the year ended December 31, 2022.

Shattuck Labs Announces Appointment of Clay Siegall, Ph.D., and Kate Sasser, Ph.D., to its Board of Directors

Retrieved on: 
월요일, 3월 4, 2024

Both Dr. Siegall and Dr. Sasser are highly successful executives and scientific pioneers who bring valuable industry experience to Shattuck.

Key Points: 
  • Both Dr. Siegall and Dr. Sasser are highly successful executives and scientific pioneers who bring valuable industry experience to Shattuck.
  • “It is a pleasure to welcome Clay and Kate, esteemed industry leaders, to our Board of Directors,” said Taylor Schreiber, M.D., Ph.D., Chief Executive Officer of Shattuck.
  • Following the next clinical updates expected mid-year, we anticipate continued expansion of and future pivotal studies for SL-172154 in multiple indications.
  • Dr. Sasser holds a Ph.D. in Integrated Biomedical Sciences from the Ohio State University as well as a B.S.

Sensei Biotherapeutics Reports Full Year 2023 Financial Results and Recent Business Highlights

Retrieved on: 
수요일, 2월 28, 2024

BOSTON, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today reported financial results for the full year 2023, and provided corporate updates.

Key Points: 
  • “2023 saw the entry of our differentiated anti-VISTA antibody, SNS-101, into clinical development,” said John Celebi, President and Chief Executive Officer.
  • Recent updates include:
    A total of 33 patients have been treated with SNS-101 +/- Libtayo in the dose escalation phase of this study.
  • On October 23, 2023 , Sensei presented a trial-in-progress poster from the Phase 1/2 clinical trial for SNS-101 at the European Society for Medical Oncology Congress (ESMO) 2023.
  • On November 1, 2023, Sensei announced the appointment of Stephanie Krebs, MS, MBA, as Chief Business Officer.

ORYZON Reports Financial Results and Corporate Update for Quarter Ended December 31, 2023

Retrieved on: 
월요일, 2월 26, 2024

Dr Carlos Buesa, Oryzon’s Chief Executive Officer, said: “Oryzon continued with a strong path in its clinical programs in the fourth quarter.

Key Points: 
  • Dr Carlos Buesa, Oryzon’s Chief Executive Officer, said: “Oryzon continued with a strong path in its clinical programs in the fourth quarter.
  • Research and development (R&D) expenses were $3.9 and $16.6 million for the quarter and twelve months ended December 31, 2023, respectively, compared to $5.0 and $18.1 million for the quarter and twelve months ended December 31, 2022.
  • General and administrative expenses were $1.2 and $4.2 million for the quarter and twelve months ended December 31, 2023, respectively, compared to $1.2 and $4.8 million for the quarter and twelve months ended December 31, 2022.
  • Net losses were $1.4 and $5.0 million for the quarter and twelve months ended December 31, 2023, respectively, compared to $1.6 and $5.9 million for the quarter and twelve months ended December 31, 2022.

LIXTE Biotechnology Enters into Exclusive Immune Oncology Patent License Agreement with NINDS and NCI

Retrieved on: 
월요일, 2월 26, 2024

PASADENA, CA, Feb. 26, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT and LIXTW) (“LIXTE” or the “Company”) today announced the signing of an exclusive patent license agreement with the National Institute of Neurological Disorders and Stroke (NINDS) and National Cancer Institute (NCI), each a component of the National Institute of Health (NIH).

Key Points: 
  • PASADENA, CA, Feb. 26, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ( Nasdaq: LIXT and LIXTW ) (“LIXTE” or the “Company”) today announced the signing of an exclusive patent license agreement with the National Institute of Neurological Disorders and Stroke (NINDS) and National Cancer Institute (NCI), each a component of the National Institute of Health (NIH).
  • The scope of this clinical research extends to checkpoint inhibitors, immunotherapy, and radiation for the treatment of cancer.
  • The agreement reinforces our dedication to pioneering research and delivering innovative solutions to patients battling cancer," he added.
  • The licensed patent rights provide LIXTE with a unique opportunity to explore and develop novel combination therapies that can potentially transform the landscape of cancer treatment.

Malaysia: Redefining Cancer Treatment Standards

Retrieved on: 
목요일, 2월 22, 2024

In recent years, Malaysia has experienced a significant increase in medical tourism, particularly in the field of cancer treatment.

Key Points: 
  • In recent years, Malaysia has experienced a significant increase in medical tourism, particularly in the field of cancer treatment.
  • This surge underscores Malaysia's growing reputation as a leading destination for individuals seeking effective and affordable cancer treatment options.
  • The country's stable political environment, modern transportation infrastructure, and welcoming hospitality ensures a safe and seamless experience for international patients seeking cancer treatment.
  • With its state-of-the-art infrastructure, skilled medical professionals, affordability, and commitment to advancing cancer care, Malaysia offers a compelling destination for individuals seeking effective cancer treatment options.

City of Hope-developed Chimeric Antigen Receptor (CAR) T Cell Therapy Shows Clinical Activity in Patients With Aggressive Brain Tumors in a Phase 1 Trial

Retrieved on: 
목요일, 3월 7, 2024

One of the main challenges for treating brain cancer is that medications have difficulty crossing the blood-brain barrier.

Key Points: 
  • One of the main challenges for treating brain cancer is that medications have difficulty crossing the blood-brain barrier.
  • Twenty-nine of the 58 patients with recurrent high-grade glioma brain tumors, mostly glioblastoma, achieved stable disease after treatment with CAR T cells for at least two months.
  • There were two partial responses, one complete response and a second complete response after additional CAR T cell therapy cycles were delivered under compassionate use.
  • The study team also included researchers from Translational Genomics Research Institute in Phoenix, which is part of City of Hope.

BostonGene Announces Publication in Collaboration with National Cancer Institute and National Institute of Allergy and Infectious Diseases in Cancer Cell

Retrieved on: 
목요일, 3월 7, 2024

Throughout its progression, FL tumor B cells undergo significant genetic changes and extensively remodel the lymphoid microenvironment to promote survival and immune evasion.

Key Points: 
  • Throughout its progression, FL tumor B cells undergo significant genetic changes and extensively remodel the lymphoid microenvironment to promote survival and immune evasion.
  • Despite the urgent need, current clinical tools inadequately predict disease behavior, underscoring the necessity for risk stratification methods, particularly for early relapsers.
  • The study, led by researchers at the National Institute of Allergy and Infectious Diseases and National Cancer Institute in collaboration with BostonGene, employed a multi-modal approach to comprehensively examine cell-intrinsic and -extrinsic factors governing disease progression and therapeutic outcomes in FL patients enrolled in a prospective clinical trial.
  • The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.